Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elebsiran and VIR-3434 in chronic hepatitis D virus infection
NL-OMON58717Phase 2Active, not recruiting
- Sponsor
- Vir Biotechnology
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of elebsiran and tobevibart in hepatitis D (HDV) (3 cohorts), sponsored by Vir Biotechnology. Primary endpoints: Composite virologic and biochemical response at Week 24 and Safety. Started May 2023; status: active, not recruiting.
02
Drugs
elebsirantobevibart
03
Conditions
hepatitis D (HDV)
Beyond the preview
Go deeper on NL-OMON58717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58717.